右丙亚胺对联用吡柔比星化疗患者的心脏保护作用

Cardio-protective effect of dexrazoxane injection for patients under theprubicin chemotherapy treatment

目的探讨右丙亚胺对行吡柔比星化疗乳腺癌患者的心脏保护作用。方法选择行吡柔比星药物化疗的乳腺癌患者80例,随机分为两组,各40例,其中观察组接受TAC(多西他赛+吡柔比星+环磷酰胺)方案加右丙亚胺静脉滴注,右丙亚胺的配制浓度为吡柔比星的10倍;对照组常规接受TAC方案加安慰剂治疗。分析并比较两组患者间不同治疗阶段的心电图、左室射血分数及不良反应。结果两组患者心电图异常差异、左室射血分数从第4周开始均有统计学意义(P<0.05);观察组在治疗前及治疗后1年随访期间,左室射血分数差异无统计学意义(P>0.05),观察组治疗期间消化道反应、脱发的发生率均明显低于对照组(P<0.05)。结论右丙亚胺能提高行含吡柔比星药物化疗的乳腺癌患者的心脏耐受性,减少不良反应。

Objective To explore the cardio-protective effect of dexrazoxane injection for breast cancer patients under theprubicin chemotherapy treatment. Methods 80 cases of breast cancer patients under theprubicin chemotherapy were randomly divided into two groups,40 cases in each group. Patients in the observation group were given TAC （taxotere＋theprubicin＋ cyclophosphamide）and dexrazoxane injection,the allocation ratio of dexrazoxane injection was 10 times of theprubicin,and patients in the control group were given TAC and placebos. Electro-cardiogram,left ventricular ejection fraction （LVEF）and adverse reactions at different treatment stages in the two groups were analyzed and compared accordingly. Results There were abnormal differences of electro-cardiogram in 2 groups and LVEF changes were statistically significant （P〈0. 05）. During the start of treatment and one year follow-up period after treatment,the LVEF of observation group had no significant difference（P〉0. 05）,the gastrointestinal reactions,occurrences of alopecia in the observation group at treatment phase were less than those in control group （P 〈0. 05）. Conclusion Dexrazoxane injection can improve cardiac resistance effect of breast cancer patients who were under theprubicin-containing chemotherapy and reduce their adverse reaction.